Examining MAHA’s jump into Real World Data (RWD), and what other industry players can learn from it

MAHA's recent strategic plan announced its intent to create a comprehensive real-world data asset to fuel research. However, any desire to move from data source to insight is likely to be more complex than merely acquiring some data. What potential pitfalls could lie ahead and what can other organizations learn from this?

Eric Fontana
Eric Fontana
Updated Oct 2, 2025 25 min read

If you watched our Mid-year policy update in July, you’ll recall my co-presenter, Yulan Egan, and I discussed the MAHA report and the omission of any mention of research-ready data assets—it seemed like such a resource would be central to support plans for broad epidemiologic investigations into a variety of chronic diseases. Well, lo and behold, when the MAHA strategy document dropped on September 9, real-world data (RWD) was number two on a long list of strategic priorities, as detailed below:

Real World Data Platform (RWDP): The NIH will link multiple datasets, such as claims information, electronic health records, and wearables data, into a single integrated dataset for researchers studying the causes of, and developing treatments for, the chronic disease crisis. The RWDP will eliminate redundancies from data collection, linkage, and compute infrastructures (including artificial intelligence (AI)/machine learning and high-throughput analytics) while maintaining rigorous privacy protections and consent protections. It will also dramatically reduce administrative overhead by relying on a unified set of data use and governance agreements.

On the surface, this is an encouraging development for at least a couple of reasons. For one, the agency (the NIH specifically) is planning on gaining access to a major repository of RWD of a variety of sources and flavors, taking a page directly out of the playbook of many large pharmaceutical and medical device companies that have been leveraging RWD for roughly two decades as an increasingly routine part of their evidence generation strategy.

Let’s talk.

Questions? Want to learn more about what Union can do for you? We’d love to hear from you.